PRINCETON, N.J., Jan. 31, 2011 /PRNewswire/ -- Laureate Pharma, Inc. has changed its name to Laureate Biopharmaceutical Services, Inc. (Laureate Biopharma) to better describe the company's positioning in the biopharmaceutical industry. The company's logo has been updated to emphasize "Laureate" and to incorporate a laurel wreath, illustrating Laureate Biopharma's reputation for scientific excellence and commitment to delivery. In addition, the company has established a new homepage (www.lbios.com).
Laureate Biopharma has been in continuous operation in its Princeton, New Jersey facility since 1981. Since 1996, Laureate Biopharma has focused exclusively on serving other developers in the biotherapeutics market.
"We are building on Laureate Biopharma's rich history and adding technologies, capacity and staff, while extending our reputation for quality and delivery," said Michael A. Griffith, Chief Executive Officer. "This name change, although subtle, speaks to our wealth of experience in protein production and a deep scientific bench, which is unique to the industry."
This name change follows the company's announcement of $20 million in secured capital. All strategically planned improvements are continuing as previously announced. These include:
For more information related to Laureate Biopharma's capabilities and ongoing improvements please visit them at their new website, www.lbios.com.
About Laureate Biopharmaceutical Services, Inc.
Laureate Biopharmaceutical Services, Inc. is a full-service biopharmaceutical contract development and manufacturing organization. Laureate Biopharma's scientists are expert in process development and cGMP production of therapeutic proteins including monoclonal antibodies and Fc-fusion proteins. In addition, the company's portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and regulatory support. Laureate Biopharma has served a global client base from its Princeton, New Jersey facility since 1981 and is a portfolio company of Saints Capital, LLC. For more information, please visit www.lbios.com.
About Saints Capital, LLC
Saints Capital is a leading direct secondary acquirer of venture capital and private equity investments in emerging growth companies around the globe. It also makes traditional direct venture capital investments on a primary basis and in special situations in technology, healthcare, consumer and industrial companies in the United States. Founded in 2000, Saints provides liquidity for private investors in such markets as investment and commercial banks, buyouts, corporate venture capital and hedge funds. Saints has more than $1 billion of committed capital under management, over 50 completed portfolio transactions and investments in more than 200 companies. For more information, please visit www.saintsvc.com.
For more information, contact: Imara Charles, Ph.D., Director of Project Management, Laureate Biopharmaceutical Services, at (609) 919-3367, or firstname.lastname@example.org or visit www.lbios.com or Jennifer Vollaro at Integrated Marketing Services at (609) 683.9055 ext. 247, or email@example.com
|SOURCE Laureate Biopharmaceutical Services, Inc.|
Copyright©2010 PR Newswire.
All rights reserved